파이프라인
한미약품은 축적된 연구 개발 기술력을 바탕으로 항암, 대사성, 심혈관 · 신장계, 희귀질환 치료제 분야에서
다양한 혁신신약을 개발하고 있습니다.
주요 파이프라인 소개 혁신신약 파이프라인 파이프라인 스냅샷

주요 파이프라인 소개

한미약품과 인류의 건강을 위한 창조와 혁신 그리고 도전 정신을 함께 할 파트너사를 찾습니다.

efocipegtrutide (LAPSTriple agonist) HM15912 (LAPSGLP-2 analog) HM15136 (LAPSGlucagon analog) HM97662 (EZH1/2 inhibitor) BH3120 (PD-L1/4-1BB BsAb) HM99462 (SOS1 inhibitor) HM16390 (LAPSIL-2 analog) LAPSGlucagon Combo
BH3120 (PD-L1/4-1BB BsAb)

OVERVIEW

BH3120 is a heterodimeric bispecific antibody (PENTAMBODY) designed to target 4-1BB and PD-L1 simultaneously to stimulate anti-tumor immune response either by inhibition of an immune checkpoint mechanism and by activation of a co-stimulatory signal in tumor microenvironment (TME) focused manner.

Non-clinical observations with BH3120, either as a monotherapy or in combination settings, consistently explain strong anti-tumor T cell activities in tumor tissue specific manner with clear dose dependency, while systemic immune response is minimally modulated.

These properties support further evaluation of the immune-modulating bispecific antibody, and BH3120 will be studied as a therapeutic candidate with multiple types of solid tumors.
Dual cancer
immunotherapy
targets
  • Inhibition of PD-1/PD-L1, T cell- co-stimulatory signaling by 4-1BB agonism
  • Conditional, PD-L1 binding dependent, 4-1BB activation in tumor tissue specific manner
  • Well balanced efficacy and safety in mono and combination settings
zoom

PUBLICATIONS

BH3120: A Novel Bispecific Antibody Targeting 4-1BB and PD-L1 with Well Balanced Efficacy and Safety Profiles
Poster, American Association for Cancer Research (AACR) 113th Annual meeting, 2022